Abstract:Objective The development of cancer vaccines deserves experimentation,specifically the immunogenicity of the new MUC1 DNA vaccine for pancreatic cancer.Methods Three strategies were combined to optimize the new MUC1 DNA vaccine.The female C57BL/6 mice were immunized,through tibial muscle injection,with 100 μg of plasmid DNA of the recombinant plasmids (pIRES2-EGFP-3VNTR group,pIRES2-EGFP-3VNTR-C1-144 group,pIRES2-EGFP 3VNTR-mIL-18 group,pIRES2-EGFP-3VNTR-C1-144-mIL-18 group,n=5) for a total volume of 100 μl.Mice inoculated with the empty vector pIRES2-EGFP (EV group,n=5) and normal saline (NS group,n=5) were used as vector and blank controls,respectively.All the mice were immunized again every two weeks.Two weeks after the third immunization,all the mice were euthanized and spleen cells were separated for CTL cytotoxic assay.Results The specific cytolysis percentages of the four groups (pIRES2-EG-FP-3VNTR,pIRES2-EGFP-3 VNTR-C1-144,pIRES2-EGFP-3VNTR-mIL-18,pIRES2-EGFP 3VNTR-C1-144-mIL-18) expressing VNTR were higher than the EV and NS group with the effector/target cells ratio (E/T) from 80:1 to 20:1 (P＜0.05).Therefore,it showed a difference among the four groups.After the primary immunization,the OD450 of the serum antibody level specific to MUC1 began to increase in the four groups which contained the gene of VNTR3 (P＜0.05).This suggests that the recombinant plasmids could induce a specific antibody response to MUC1,and showed no remarkable difference among the four groups.IFN-γ serum cytokine among the four groups were higher than that of the EV and NS groups (P＜0.05).There was a significant difference of OD450 between the groups containing mIL-18 pIRES2-EGFP-3VNTR-mIL-18,pIRES2-EGFP-3VNTR-C1-144-mIL-18) and those not (pIRES2-EGFP-3VNTR,pIRES2-EGFP-3VNTR-C1-144,)(P＜0.05).Conclusions In conclusion,all of the four recombinant plasmids could induce MUC1 specific CTL and antibodies responses,and C1-144 and IL-18 could enhance the immunogenicity of plasmids.

Expression and identification of recombinant human IL-2 and MUCI fusion protein in E.coli BL21

Construction and identification of recombinant human interleukin-2 in vaccine virus

MUC1/Y plasmids as tumor vaccine in the experimental study of anti-tumor roles in the bladder cancer

The immunological investigation for anti-tumor roles of MUC1 vaccine in the bladder cancer

THE STUDY OF EXPRESSION AND FUNCTION OF ANTIBODY-CYTOKINE FUSION PROTEIN 183B2scfv-Interleukin 2

The optimized construction and cell transfection assay of new MUC1 DNA vaccine for pancreatic cancer

Molecular Cloning of Human IL-7cDNA and Construction of Eukaryotic Vector Expressing Hil-7

The immunogenicity of the new MUC1 DNA vaccine for pancreatic cancer

Construction of Eukaryotic Expression Vector of Interleukin-2 Gene from Xiaoshan Chicken and Its Expression in Vero Cells

Study on the Expression and Immune Enhancement of IL-18-GPI Fused Protein

Construction and its Antitumor Efficiency of Murine Interleukin 21 Tumor Vaccine

Expression Of Fusion Il2-B7.1(Igv+C) And Effects On T Lymphocytes

Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles

Establishment of the interleukin-2 gene transferred human colorectal cancer cell vaccine

[Construction of Fusion Gene Between IgGHV and IL-2 As IgHV Nucleic Acid Vaccine Against Lymphoma].

Investigation on the anti-tumor effect and mechanisms of the glycosyl phosphatidylinositol modified routine IL-21 tumor vaccine

Investigation on the anti-tumor effect and mechanisms of the glycosyl phosphatidylinositol modified murine IL-21 tumor vaccine

Synthesis and immunological evaluation of the unnatural β-linked mucin-1 Thomsen-Friedenreich conjugate

Construction and Expression of Antibody-cytokine Fusion Protein in Eukaryotic Cells

A Novel Recombinant Tandem Repeat Dna Vaccine Targeting at Muc1

[Construction and Prokaryotic Expression of Recombinant Gene EGFRvIII HBcAg and Immunogenicity Analysis of the Fusion Protein].